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(http://creativecommobiofeedback Vibrance Kegel Device (VKD), compared to PFMEs alone, in treating stress urinary
incontinence (SUI).MATERIALS AND
METHODS
This was a pilot prospective, randomized trial of women aged 18 years with SUI symptoms who
underwent PFMEs at University Malaya Medical Centre from October 2011 to October 2013.
The patients were randomly divided into two groups: control (PFMEs alone) and VKD (PFMEs
with VKD biofeedback). The patients underwent 16 weeks of pelvic ﬂoor training, during which
they were assessed using Australian pelvic ﬂoor questionnaires and modiﬁed Oxford scales for
pelvic ﬂoor muscle strength at week 0, 4, and 16.RESULTS Forty patients were recruited (control 19, VKD 21). Three patients in the control group dropped
out during week 16 training, whereas the VKD group had no dropouts. The VKD group reported
signiﬁcantly earlier improvement in SUI scores, as assessed by the Australian pelvic ﬂoor ques-
tionnaires (P ¼ .035) at week 4. However, there was no signiﬁcant difference between the groups’
SUI scores at week 16. Pelvic ﬂoor muscle strength was signiﬁcantly better in the VKD group at
week 4 (P ¼ .025) and week 16 (P ¼ 0.001). The subjective cure rate was similar in both groups
at week 16 (62.5% for control and 61.9% for VKD) (P ¼ 0.742).CONCLUSION Using the VKD resulted in signiﬁcant early improvement in SUI scores, and pelvic muscle strength
had improved signiﬁcantly by the end of the study. The VKD proved useful as an adjunct for pelvic
ﬂoor training. UROLOGY 86: 487e491, 2015. 2015 The Authors. Published by Elsevier Inc. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).rinary incontinence is a common and debili-
tating condition affecting 15% of adult popu-Ulation in America and more than one-third of
women above the age of 60.1 Pelvic ﬂoor muscle exercises
(PFMEs) have been the ﬁrst-line treatment for urinary
incontinence since Arnold Kegel introduced them half
a century ago.2 However, studies have shown that
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hisolated pelvic ﬂoor contraction following written or verbal
instruction.3,4 Biofeedback was subsequently introduced
into clinical practice with the aim of enhancing the effects
of PFMEs and improving muscle function.5
The biofeedback devices used, compared with PFMEs
alone, have produced variable results in the treatment of
stress or mixed urinary incontinence6-11 (Supplemental
Table S1). Out of 6 studies, only Burgio et al11 and Burns
et al9 reported statistically signiﬁcant results using biofeed-
back devices with PFMEs. Burgio et al noted a statistically
signiﬁcant difference between treatment groups in favor of a
biofeedback device for the average reduction of inconti-
nence and improvement in the contractional force of the
pelvic ﬂoor.11 Burns et al showed statistically signiﬁcant
improvement in the contractional force of the pelvic ﬂoor,
but not in the average reduction of incontinence.9
The Vibrance Kegel Device (VKD) is a new biofeedback
tool designed by Bioinﬁnity Pte Ltd (Fig. 1A). As a T-shaped
device with a pressure-sensitive body (to detect vaginal
squeeze pressure), sheath, and outer body, the VKD uses
vibrational pulses as active biofeedback on pelvic musclettp://dx.doi.org/10.1016/j.urology.2015.06.022
0090-4295/15
487
Figure 1. CONSORT (Consolidated Standards for Reporting Trials) ﬂow diagram for patient recruitment and analysis. Box A
shows the VKD. The red boxes indicate the VKD group whereas the blue boxes indicate the control group.contractions. The outer sheath has varying degrees of resis-
tance for different training intensities. Proper pelvic muscle
contractions are detected by the device, which provides the
user with vibrational feedback. The VKD is user-friendly,
mobile, and approved for use by the FDA (K141893),
providing patients with ﬂexibility in their training schedules.
In the current study, we assessed the VKD’s effective-
ness when used in conjunction with PFMEs, compared
with PFMEs alone, for treating female stress urinary in-
continence (SUI).
MATERIALS AND METHODS
Study Design
The study was a nonblinded, randomized controlled pilot study
performed from October 2011 to October 2013 at University
Malaya Medical Centre (UMMC). Ethical approval was ob-
tained from the UMMC ethics committee (Report 877.7).
Female patients with SUI were recruited from urological, gyne-
cological, and primary care clinics. Two standard questions about
stress (“Doyou leak urinewith activities such as coughing, sneezing,
or running?”) and urge urinary incontinence (“Does urine leak
when you rush/hurry to the toilet?”) were used to determine the
patient eligibility. Only women predominantly suffering from SUI
were recruited. The exclusion criteria included previous inconti-
nence surgery, concomitant medical treatment for urinary488incontinence, urinary tract infection, and neurologic or psychiatric
disease. All of the participants provided written informed consent.
Simple randomizationwas used for this study. Theparticipantswere
randomized by casting lots with a box containing equal numbers of
lots for the control and VKD groups. The lots, which were
replenished before each cast, decided the participants’ allocation.
After randomization, all of the participants underwent a
standardized assessment using the Australian pelvic ﬂoor ques-
tionnaire (APFQ),12 followed by a physiotherapist-conducted
pelvic ﬂoor assessment using the modiﬁed Oxford scale
(MOS) to assess patients’ suitability for planned treatment and
collection of baseline data. The questionnaire and pelvic ﬂoor
muscle assessment were conducted before training at week 0, 4,
and 16 by an evaluator and a physiotherapist, respectively.
Outcome Measures
The primary outcomes for this study were SUI score and pelvic
ﬂoor muscle strength, with secondary outcomes of total urinary
score, social life score, bothersome score, and subjective cure.
The evaluations of both groups were conducted before and after
treatment completion by 1 nonblinded physiotherapist and 1
nonblinded investigator.
The APFQ,12 which was used to assess the urinary score, is a
validated questionnaire comprising 41 questions divided into 4
domains: bladder function, bowel function, prolapse symptoms,
and sexual function. We chose to focus on the bladder function
domain, which contains 15 questions (see Supplementary Fig. S1).UROLOGY 86 (3), 2015
Table 1. Demographic and outcome variables at baseline
Demographic
Variables
VKD Group
(n ¼ 21)
Control Group
(n ¼ 19) P
Age (y) 50.7 (11.0) 53.2 (14.3) .538
Race (n, %) .859
Malay 12 (57.1) 10 (52.6)
Chinese 4 (19.0) 5 (26.3)
Indian 5 (23.8) 4 (21.1)
Parity 3.2 (0.9) 2.8 (1.2) .284
SVD (n, %) .962
0 1 (4.8) 2 (11.1)
1 1 (4.8) 1 (5.6)
2 8 (38.1) 6 (33.3)
3 7 (3.3) 6 (33.3)
>3 4 (19.0) 3 (16.7)
Forceps (n, %) .651
No 15 (71.4) 14 (77.8)
Yes 6 (28.6) 4 (22.2)
Vacuum (n, %) 1.000
No 20 (95.2) 17 (94.4)
Yes 1 (4.8) 1 (5.6)
LSCS (n, %) .379
No 15 (71.4) 15 (83.3)
Yes 6 (28.6) 3 (16.7)
Menopause (n, %) .184
No 11 (52.4) 6 (31.6)
Yes 10 (47.6) 13 (68.4)
SUI score 2.6 (0.7) 2.3 (0.9) .217
Total urinary score 15.8 (7.7) 11.6 (4.4) .045
Bothersome score 2.3 (0.7) 1.9 (1.0) .118
Social life score 2.1 (1.0) 1.6 (1.3) .163
Pelvic ﬂoor muscle
strength (MOS)
2.3 (0.7) 2.6 (0.8) .304
LSCS, lower segment Caesarean section; MOS, modiﬁed oxford
scale; SUI, stress urinary incontinence; SVD, spontaneous vaginal
delivery; VKD, Vibrance Kegel Device.
Data presented as mean (standard deviation) unless stated
otherwise.The total urinary score represented the total score for the bladder
function domain, whereas the SUI score was speciﬁcally based on
question 6, the social life score was based on question 14, and the
bothersome score was based on question 15.
For the pelvic ﬂoor muscle assessment, our physiotherapist
used the MOS13 to measure muscle strength on a 6-point Likert-
type scale (0 ¼ no contraction, 1 ¼ ﬂicker, 2 ¼ weak, 3 ¼
moderate [with lift], 4 ¼ good [with lift], 5 ¼ strong [with lift]).
The participants were asked to perform three maximum
voluntary contractions and the best was taken as the score.
Both groups were encouraged to do PFMEs daily and record
their exercise frequency. At the end of treatment, the women
treated were questioned regarding their perception of urinary
leakage improvement. They were given the response option of
unchanged or improved, and if they reported improvement, they
were asked whether they considered themselves continent. The
participants with no improvement were followed-up in a urology
clinic with different treatment options.
Treatment Protocol
All of the participants underwent a standardized pelvic ﬂoor
muscle training protocol,3 which consists of endurance and speed
training. Endurance training involved slow velocity close to
maximum contraction for 3-10 seconds, followed by relaxation for
3-10 seconds. Speed training involved quick, moderately strong
contractions for 2 seconds followed by relaxation for 2 seconds.
The participants were required to complete 3-5 sets of each type
of training; that is, 10 contractions in a row or until fatigue.
The participants were treated individually by the physio-
therapist in monthly sessions of 20 minutes for 16 weeks. During
the sessions, the participants were re-educated on pelvic ﬂoor
training and their progression was noted.
For the VKD group, during the initial training under the
physiotherapist’s supervision, the device was placed inside the
vagina and the participant conducted PFME training according
to the standard protocol. Both groups were encouraged to do daily
pelvic ﬂoor training at home, one group with biofeedback (VKD)
and the other without (control). The questionnaire and pelvic
ﬂoor muscle assessment were conducted at week 0, 4, and 16.
Statistical Analysis
All of the statistical analyses were performed using SPSS soft-
ware (version 17; SPSS Inc., Chicago, IL). The c2-test and t-
test were used to verify the homogeneity of the groups at
baseline. For intragroup analysis, the Wilcoxon test was used. A
subjective cure was analyzed using the c2-test. The differences
were considered signiﬁcant when the P value was <.05.
RESULTS
Forty participants were recruited and randomized (control
19; VKD 21) (Fig. 1). The VKD group had no dropouts,
whereas 15.8% of the participants from the control
group dropped out. The reasons given for dropping out were
family death, lack of transportation, and work commitments.
There were no signiﬁcant differences in outcome var-
iables between both groups at baseline, except for total
urinary score (P ¼ .045), which showed a signiﬁcant
difference (Table 1). All of the participants had regular
pelvic ﬂoor muscle training during the 16 weeks treat-
ment period, and there was no signiﬁcant difference in
the training frequency between the groups.UROLOGY 86 (3), 2015At 4 weeks, the SUI score improvement showed a
signiﬁcant difference in the VKD group compared with
the control group (P ¼ .017). The pelvic ﬂoor muscle
strength (MOS score) improvement also showed a sig-
niﬁcant difference favoring the VKD group (P ¼ .027).
No signiﬁcant difference was seen in the total urinary
score (P ¼ .157), social life score (P ¼ .554), or both-
ersome score (P ¼ .906) between the groups (Table 2).
At 16 weeks, there was a signiﬁcant difference in the
MOS scores in the VKD group (P ¼ .003). However, the
SUI score improvement was not signiﬁcant between the
groups (P ¼ .982). Comparison of the secondary outcome
variables such as total urinary, social life, and bothersome
scores between the groups were not signiﬁcant at the end
of study (Table 2).
An intragroup analysis showed that both groups exhibi-
ted statistically signiﬁcant improvements in SUI score and
pelvic muscle strength at 16 weeks, compared with before
training and after 4 weeks of training (Table 3).
Subjective cure (number of women stating they are
continent after the treatment) showed no statistically
signiﬁcant difference (P ¼ .742) between groups after
week 16 (Table 2).489
Table 2. Number of patients with improvement in outcome
variables
Outcome Variables VKD Group Control Group P
Stress urinary incontinence score (APFQ question 6)
4 wk 11/19 (57.8) 11/19 (57.8) .017
16 wk 13/16 (81.3) 13/16 (81.3) .982
Pelvic muscle strength (MOS score)
4 wk 5/14 (35.7) 0/11 (0.0) .027
16 wk 14/16 (87.5) 4/12 (33.3) .003
Social life score (APFQ question 14)
4 wk 13/21 (61.9) 10/19 (52.6) .554
16 wk 16/21 (76.2) 9/16 (56.3) .199
Bothersome score (APFQ question 15)
4 wk 14/21 (66.7) 13/19 (68.4) .906
16 wk 18/21 (85.7) 11/16 (68.8) .214
Total urinary score (APFQ Q1-15) (mean  SD)
4 wk 7.9  6.8 5.2  4.7 .157*
16 wk 11.3  8.3 7.8  5.1 .157*
Subjective cure (APFQ question 6; score ¼ 0)
4 wk 6/21 (28.6) 5/19 (26.3) .873
16 wk 12/21 (57.1) 10/16 (62.5) .742
APFQ, Australian pelvic ﬂoor questionnaire; SD, standard devia-
tion; other abbreviations as in Table 1.
Data presented as number of patients (percentage) unless
stated otherwise.
Comparisons using Pearson’s c2-tests except *t-test.
Table 3. Improvement in SUI score and pelvic ﬂoor muscle
strength from baseline to after treatment within each group
Outcome
Variables VKD Group P Control Group P
Stress urinary incontinence score
0-4 wk 19/21 (90.5) <.001 11/19 (57.9) .006
0-16 wk 17/21 (81.0) <.001 13/16 (81.3) .001
Pelvic muscle strength (MOS score)
0-4 wk 5/15 (33.3) .025 0/11 (0) 1.000
0-16 wk 14/16 (87.5) .001 4/12 (33.3) .059
Abbreviations as in Table 1.
Data presented as number of patients with improvement
(percentage).
P value obtained using Wilcoxon signed rank test.COMMENT
In this study, after 16 weeks of treatment, both groups
showed signiﬁcant improvement in SUI symptoms, as
shown by improved SUI scores and pelvic muscle
strength. The subjective cure rate was 57.1% in the VKD
group and 62.5% in the control group. This result is in
line with the Cochrane meta-analysis comparing pelvic
ﬂoor muscle training with no treatment.14
Women treated with the VKD showed signiﬁcantly
earlier improvement in SUI symptoms, reﬂected in their
SUI scores and pelvic ﬂoor muscle strength at 4 weeks. In
this study, the VKD provided patients with easy, accurate
recognition of which pelvic ﬂoor muscles needed to be
contracted, enhancing correct pelvic ﬂoor training. This
may have led to earlier improvement in pelvic muscle
tone and neuromuscular function and a better urethral
closure mechanism during a rise in intra-abdominal
pressure. Another possible explanation for this result is
that early improvement provided more motivation and
encouragement for patients to continue doing PFMEs.
These results essentially showed that the VKD played an
important role by aiding patients in early recognition of
the appropriate muscles to exercise.
PFMEs with VKD were not statistically signiﬁcantly
different from PFMEs alone after 16 weeks of training,
although the VKD group still had better SUI scores and
signiﬁcantly better pelvic muscle strength by the end of the
study. Mørkved et al15 conducted a single-blinded, ran-
domized controlled trial comparing pelvic ﬂoor exercises
with and without a vaginal pressure probe. They reported
better objective cure (58% in the biofeedback group and
46% in the control group) and subjective cure (69% in
the biofeedback group and 50% in the control group).490However, there was no statistically signiﬁcant difference
between the groups. Bø et al16 and Arvonen et al17 con-
ducted randomized controlled trials comparing PFMEs
with vaginal cones and found no statistically signiﬁcant
difference in the number of self-reported cures between the
groups. A recent Cochrane meta-analysis comparing pelvic
ﬂoor muscle training with and without biofeedback did not
conclusively ﬁnd a signiﬁcant difference in the cure rate.18
Our ﬁndings correspond to the aforementioned randomized
controlled trials and meta-analysis.
There is no standardized outcome measure for urinary in-
continence. The Urodynamic Society and the International
Continence Society recommend using urinary leakage to
evaluate treatment effects. We did not use pad tests in
this study because the short pad test is difﬁcult to perform
in elderly women. Furthermore, the Cochrane meta-
analysis reported that pad test outcomes did not corre-
spond very well with data on leakage episodes, and that
variability in reporting restricted the use of pad test results
in comparing data from different studies.14 Pad test
evaluation should be considered for future studies
regarding this biofeedback device as an objective assess-
ment of urinary incontinence.
In this study, the Oxford grading scale is used to assess
pelvic muscle strength. Although pelvic ﬂoor manometry
was not used to assess pelvicmuscle strength, Da Roza et al19
revealed a moderate correlation between peak pressure on
manometry and theOxford grading scale score.Morin et al20
also found a signiﬁcant correlation between vaginal digital
assessment with dynamometric measurements for continent
and incontinent women, although themeanmaximal forces
between two adjacent categories do not differ. Thus, digital
pelvic ﬂoor assessment is a feasible outcome measure.
Moreover, the MOS score was not complete due to patients
refusing pelvic ﬂoor assessment during menstruation.
The total urinary score was not used as a primary
outcome measure because the score considers urge in-
continence and overactive bladder symptoms, whereas
our study focused on SUI symptoms. The signiﬁcant dif-
ference in total urinary score between the groups at
baseline could be due to the small number of participants,
the simple randomization method, or the nonblinding
method used in this study. However, the total urinary
score was not signiﬁcant between the two groups.UROLOGY 86 (3), 2015
Bø et al16 ran a randomized controlled trial comparing
pelvic ﬂoor exercise, vaginal cones, and electric stimulation.
They found that 54% of patients achieved subjective cure
after 6months.Our study showed similar subjective cure rates
of 57.1% in the VKD group and 62.5% in the control group.
Subjective measures of the severity of incontinence
and its effect on quality of life and the degree of bother
experienced are important when evaluating urinary in-
continence. In our study, parameters such as social life
improvement and bothersome score were better in the
VKD group, although not statistically signiﬁcant. This
could be due to the small sample size. It is important to
note that the quality of life improvement recorded in the
VKD group was mainly due to the ease of using the de-
vice, which led to a better compliance rate and results.
Compliance with treatment is important in muscle
strength training because the results depend heavily on
regular training. The VKD group exhibited better
compliance, reﬂected in the lack of dropouts, whereas the
control group had a 15.8% dropout rate. Studies on
biofeedback such as vaginal cones training have reported
poor compliance due to poor device tolerance; for
example, Olah et al21 reported an initial dropout rate of
27% that further increased to 42% after 6 months. Such
increased dropout rates are possibly caused by adverse
events, as those reported by Bø et al,16 including the
inability to use cones, pain, vaginitis, and bleeding.
All of our patients were compliant with the VKD
training, as they found the device convenient to use and
easy to clean. The patients in the VKD group gave mostly
positive feedback regarding the device in terms of ease of
use, portability, water resistance, and ease of cleaning.
None of the patients reported adverse events, but one
noted rust developing near the base. The patients were
advised to keep the VKD device dry after washing it and
battery life was good, with a mean usage of 8 weeks.
The patients in our study underwent monthly physio-
therapy visits, which were comparatively less than the
weekly physiotherapy required in other biofeedback trials
such as those conducted by Mørkved et al,15 Olah et al,21
and Kondo et al.22 In our trial, the patients in both groups
were compliantwith treatment, as their exercise frequencies
were similar despite less follow-up. This equates to time and
cost savings for patients and healthcare services.
CONCLUSIONS
This study showed that the VKD is a good adjunct to
pelvic ﬂoor exercises, as it helps patients beneﬁt from
pelvic ﬂoor muscle training. It is a small, portable device
that can be applied in clinical practice to provide patients
with a convenient way to perform effective pelvic ﬂoor
exercises. However, further studies should be performed
to reach a deﬁnite conclusion about its efﬁcacy.References
1. Fantl JA, Wyman JF, McClish DK, et al. Efﬁcacy of bladder training in
older women with urinary incontinence. JAMA. 1991;265:609-613.UROLOGY 86 (3), 20152. Kegel AH. Progressive resistance exercise in the functional restora-
tion of the perineal muscles. Am J Obstet Gynecol. 1948;56:238-249.
3. Bø K, Kvarstein B, Hagen RR, Larsen S. Pelvic ﬂoor muscle exercise
for the treatment of female stress urinary incontinence: II. Validity
of vaginal pressure measurements of pelvic ﬂoor muscle strength and
the necessity of supplementary methods for control of correct
contraction. Neurourol Urodyn. 1990;9:479-487.
4. Bump RC, Hurt WG, Fantl JA, Wyman JF. Assessment of Kegel
pelvic muscle exercise performance after brief verbal instruction.
Am J Obstet Gynecol. 1991;165:322-329.
5. Knight SJ, Laycock J. The role of biofeedback in pelvic ﬂoor re-
education. Physiotherapy. 1994;80:145-148.
6. Shepherd AM, Montgomery E, Anderson RS. Treatment of genuine
stress incontinencewith anewperineometer.Physiotherapy. 1983;69:113.
7. Castleden CM, Dufﬁn HM, Mitchell EP. The effect of physio-
therapy on stress incontinence. Age Ageing. 1984;13:235-237.
8. Taylor K, Henderson J. Effects of biofeedback and urinary stress
incontinence in older women. J Gerontol Nurs. 1986;12:25-30.
9. Burns PA, Pranikoff K, Nochajski TH, et al. A comparison of
effectiveness of biofeedback and pelvic muscle exercise treatment of
stress incontinence in older community-dwelling women. J Gerontol.
1993;48:167-174.
10. Berghmans LC, Frederiks CM, de Bie RA, et al. Efﬁcacy of biofeed-
back, when included with pelvic ﬂoor muscle exercise treatment, for
genuine stress incontinence. Neurourol Urodyn. 1996;15:37-52.
11. Burgio KL, Robinson JC, Engel BT. The role of biofeedback in
Kegel exercise training for stress urinary incontinence. Am J Obstet
Gynecol. 1986;154:8-64.
12. Baessler K, O’Neill S, Maher C, Battistutta D. A validated female
pelvic ﬂoor questionnaire for clinicians and researchers. Neurourol
Urodyn. 2004;23:398-399.
13. Laycock J. Clinical evaluation of the pelvic ﬂoor. In: Schussler B,
Laycock J, Norton P, Stanton SL, eds. Pelvic Floor Re-education. 1st
ed. Chap 2.2. London: Springer; 1994:42-48.
14. Dumoulin C, Hay-Smith J. Pelvic ﬂoor muscle training versus no
treatment, or inactive control treatments, for urinary incontinence
in women. Cochrane Database Syst Rev. 2010;1:CD005654.
15. Mørkved S, Bø K, Fjørtoft T. Effect of adding biofeedback to pelvic
ﬂoor muscle training to treat urodynamic stress incontinence. Obstet
Gynecol. 2002;100:730-739.
16. Bø K, Talseth T, Holme I. Single blind, randomised controlled trial
of pelvic ﬂoor exercise, electrical stimulation, vaginal cones, and no
treatment in management of genuine stress incontinence. BMJ.
1999;318:487-493.
17. Arvonen T, Fianu-Jonasson A, Tyni-Lenne R. Effectiveness of two
conservative modes of physical therapy in women with urinary stress
incontinence. Neurourol Urodyn. 2001;20:591-599.
18. Herderschee R, Hay-Smith J, Herbison GP, et al. Feedback or
biofeedback to augment pelvic ﬂoor muscle training for urinary in-
continence inwomen.CochraneDatabase Syst Rev. 2011;7:CD009252.
19. Da Roza T, Mascarenhas T, Araujo M, et al. Oxford Grading Scale
vs manometer for assessment of pelvic ﬂoor strength in nulliparous
sports students. Physiotherapy. 2013;99:207-211.
20. Morin M, Dumoulin C, Bourbonnais D, et al. Pelvic ﬂoor maximal
strength using vaginal digital assessment compared to dynamometric
measurements. Neurourol Urodyn. 2004;23:336-341.
21. Olah KS, Bridges N, Denning J, Farrar DJ. The conservative
management of patients with symptoms of stress incontinence: a
randomized, prospective study comparing weighted vaginal cones
and interferential therapy. Am J Obstet Gynecol. 1990;162:87-92.
22. Kondo A, Yamada Y, Niijima R. Treatment of stress incontinence
by vaginal cones: short- and long-term results and predictive pa-
rameters. Br J Urol. 1995;76:464-466.
APPENDIX
SUPPLEMENTARY DATA
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.urology.
2015.06.022.491
